The preparation of 13-methylgon-4-enes and novel 13-polycarbonalkylgon-4-enes by a new total synthesis is described. 13-Alkylgon-4-enes having progestational, anabolic and androgenic activities are prepared by forming a tetracylic gonane structure unsaturated in the 1,3,5(10),9(11) and 14-positions, selectively reducing in the B- and C-rings, and converting the aromatic A-ring compounds so-produced to gon-4-enes by Birch reduction and hydrolysis.
Applications for levonorgestrel in preparing anti-ovarian cancer products
申请人:SHANGHAI JIAO TONG UNIVERSITY
公开号:US10792291B2
公开(公告)日:2020-10-06
This invention discloses uses for levonorgestrel in preparing anti-ovarian cancer products. This invention provides uses for levonorgestrel in the preparation of products to treat ovarian cancer. From carrying out cancer drug repositioning for the FDA- and CFDA-approved drug levonorgestrel, experiments for this invention show, based on screening of non-anti-cancer drugs for various cancer cell lines (tissue types) and mutation sites, that levonorgestrel has a new use as an anti-ovarian cancer medication, thus achieving a new purpose for an old drug.
本发明公开了左炔诺孕酮在制备抗卵巢癌产品中的用途。本发明提供了左炔诺孕酮在制备治疗卵巢癌产品中的用途。通过对美国 FDA 和 CFDA 批准的药物左炔诺孕酮进行抗癌药物重新定位,本发明的实验表明,根据对各种癌细胞系(组织类型)和突变位点的非抗癌药物筛选,左炔诺孕酮具有抗卵巢癌药物的新用途,从而实现了老药新用。
APPLICATIONS FOR LEVONORGESTREL IN PREPARING ANTI-OVARIAN CANCER PRODUCTS
申请人:SHANGHAI JIAO TONG UNIVERSITY
公开号:US20180185389A1
公开(公告)日:2018-07-05
This invention discloses uses for levonorgestrel in preparing anti-ovarian cancer products. This invention provides uses for levonorgestrel in the preparation of products to treat ovarian cancer. From carrying out cancer drug repositioning for the FDA- and CFDA-approved drug levonorgestrel, experiments for this invention show, based on screening of non-anti-cancer drugs for various cancer cell lines (tissue types) and mutation sites, that levonorgestrel has a new use as an anti-ovarian cancer medication, thus achieving a new purpose for an old drug.
US3959322A
申请人:——
公开号:US3959322A
公开(公告)日:1976-05-25
Synthesis of gon-4-enes
申请人:Smith; Herchel
公开号:US04002746A1
公开(公告)日:1977-01-11
1. A therapeutic composition having progestational activity comprising as active ingredient a 17-aliphatic carboxylic acid ester of 17.alpha.-ethynyl-18-methyl-19-nortestosterone and a pharmaceutical carrier for said compound.